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Objective: In vivo differentiation of cardiac myocytes is associated with downregulation of the glucose transporter isoform GLUT1 and
upregulation of the isoform GLUT4. Adult rat cardiomyocytes in primary culture undergo spontaneous dedifferentiation, followed by
spreading and partial redifferentiation, which can be influenced by growth factors. We used this model to study the signaling mechanisms
modifying the expression of GLUT4 in cardiac myocytes. Results: Adult rat cardiomyocytes in primary culture exhibited spontaneous
upregulation of GLUT1 and downregulation of GLUT4, suggesting resumption of a fetal program of GLUT gene expression. Treatment with
IGF-1 and, to a minor extent, FGF-2 resulted in restored expression of GLUT4 protein and mRNA. Activation of p38 MAPK mediated the
increased expression of GLUT4 in response to IGF-1. Transient transfection experiments in neonatal cardiac myocytes confirmed that p38
MAPK could activate the glut4 promoter. Electrophoretic mobility shift assay in adult rat cardiomyocytes and transient transfection
experiments in neonatal cardiac myocytes indicated that MEF2 was the main transcription factor transducing the effect of p38 MAPK
activation on the glut4 promoter. Conclusion: Spontaneous dedifferentiation of adult rat cardiomyocytes in vitro is associated with
downregulation of GLUT4, which can be reversed by treatment with IGF-1. The effect of IGF-1 is mediated by the p38 MAPK/MEF2 axis,
which is a strong inducer of GLUT4 expression.
D 2004 European Society of Cardiology. Published by B.V. All rigths reserved.Keywords: Gene expression; Growth factors; Cell culture/isolation; Cell differentiation; MAP kinase1. Introduction
Cardiac myocytes use a variety of substrate for energy
production, including free fatty acids, glucose, lactate and
ketone bodies. Substrate selection is developmentally regu-
lated. During the perinatal period, substrate metabolism
shifts from predominant non-oxidative glucose utilization
to predominant fatty acids oxidation [1]. This shift is
associated with a change in the expression of a number of
regulatory proteins of glucose and fatty acids metabolism0008-6363/$ - see front matter D 2004 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2004.06.005
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Medical School, Rue Du Bugnon, CH-1011 Lausanne, Switzerland.[2–5], including glucose-transporting proteins. Specifically,
the ubiquitous glucose transporter GLUT1 is largely
replaced by the insulin-regulated isoform GLUT4 [2,3,5].
Myocardial hypertrophy is associated with changes in
glucose metabolism characterized by increased basal glucose
uptake and insulin resistance [6,7]. Basal uptake of glucose
is mediated GLUT1, which is expressed at a low level in the
normal adult heart, but is increased in rat models in vivo
during post-ischemic reperfusion [8] or cardiac failure fol-
lowing remodeling after large myocardial infarction [9].
Conversely expression of GLUT4 is decreased [8,9]. Obser-
vations in GLUT4-null mice indirectly suggests that down-
regulation of GLUT4 may be involved in the pathogenesis of
hypertrophy [10,11]. In addition, GLUT4 deficiency is
associated with impaired post-ischemic recovery [12].
Adult rat cardiomyocytes (ARC) in primary culture re-
express markers of hypertrophy, including ANF and a-ed by B.V. All rigths reserved.
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fetal and perinatal life, but are downregulated during mat-
uration [13]. The growth factors FGF-2 and IGF-1 modulate
this process in opposite directions [14–16]. FGF-2 accel-
erates expression of markers of dedifferentiation, while IGF-
1 promotes a more differentiated phenotype.
In the present study, we used the model of ARC in
primary culture, first, to determine the influence of growth
factors affecting differentiation of cardiac myocytes on
expression of GLUT4 and, second, to decipher the signaling
pathways involved in the control of expression of GLUT4.2. Materials and methods
2.1. Animals
We obtained male Sprague–Dawley rats (100–110 g)
from IFFA CREDO (L’Arbresle, France). Newborn Spra-
gue–Dawley rats (1–3 days) were from the Geneva Uni-
versity School of Medicine animal facility. The ethical
committee of the Geneva University School of Medicine
and the Geneva State Veterinary Office approved the study
protocol, which conforms with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996).
2.2. Adult rat cardiomyocytes culture
Adult rat cardiomyocytes (ARC) were isolated by retro-
grade perfusion of the hearts with collagenase (type II,
Biochrom) [17,18]. Cells were plated onto dishes or cham-
ber slides (Lab-Tek, Nalge Nunc) previously coated with
0.1% gelatin and incubated overnight with culture medium
containing 20% fetal calf serum (FCS). Plating density was
approximately 20,000 cells/cm2. Culture medium was M199
with Earle’s salts (Life Technologies) supplemented with 20
mM creatine, 100 AM cytosine-h-D-arabinofuranoside and
1% FCS.
Recombinant human Fibroblast Growth Factor-2 (FGF-
2, Boehringer-Mannheim) and recombinant human Insulin-
like Growth Factor-1 (IGF-1, Bachem, Basel, Switzerland)
was added from 10 mM CH3COOH stock solutions to the
medium at the time of plating (day 0). The medium was
replaced on day 2.
The MAP kinase inhibitors U0126 (Promega) and
SB203580 (Calbiochem) were also added at the time of
plating from DMSO stock solutions. The final concentration
of DMSO in culture medium (0.1%) had no effect on the
expression of GLUT4.
2.3. Neonatal rat cardiomyocytes culture
Neonatal rat cardiomyocytes (NRC) were isolated by
collagenase digestion and maintained in Dulbecco’s modi-fied Eagle’s medium (DMEM)/medium 199 (4:1) supple-
mented with penicillin and streptomycin [19]. Cells were
plated at a density of 2.5 105 cells per 3.5-cm dish or
5 105 cells per 6-cm dish.
2.4. Plasmids and NRC transfection
Marcelle Lavau kindly donated the plasmid p2.2Luc-
2212GLUT4 containing 2.2 kb of the rat glut4 promoter
[20]. We excised the glut4 promoter with KpnI and NheI
and inserted it into the multiple cloning site of pGL3basic
(Promega). The resultant plasmid pLuc-GT4 encodes Pho-
tinus luciferase under the control of the rat glut4 promoter.
Using the QuickChange mutagenesis kit (Stratagene), we
mutated the MEF2 responsive element in position  466
to  457 in the rat glut4 promoter from CTAAAAATAG to
CTAGCCTTAG to generate the plasmid pLuc-GT4-MEF2-
mut. Andrew Thorburn kindly provided the pSRa-
MEK6DD plasmid encoding a constitutively active mutant
of MEK6 [21]. All plasmids were cotransfected with a
plasmid encoding Renilla luciferase under the control of
the SV40 promoter (pRL-SV40, Promega). Transient trans-
fection of NRC was performed using the calcium phos-
phate precipitation method [19]. Transfection mixes
contained 1 Ag of pLuc-GT4, 1 Ag of pRL-SV40 and 1
Ag of the selected expression plasmid or the empty vector.
Photinus and Renilla luciferase activity was measured 2
days after transfection with the Dual Luciferase Reporter
kit (Promega).
2.5. Immunoblot analysis
ARC in one 6-cm dish were extracted in 200 Al RIPA
(150 mM NaCl, 9.1 mM Na2HPO4, 1.7 mM NaH2PO4, pH
7.4, 1:100 protease inhibitor cocktail (Sigma P8340), 5
mM NaF, 10 mM Na2h-glycerophosphate, 10 mM Na2par-
anitrophenyl phosphate, 1 mM NaVO3). Extracts were
clarified by centrifugation (12,000 rpm for 5V) and super-
natants were used for SDS-PAGE and immunoblotting
[22]. Antibodies against phosphorylated and non-phos-
phorylated forms of ERK1/2, Akt and p38 MAPK were
from Cell Signalling Technologies (Beverly, MA). A rabbit
polyclonal antibody against GLUT1 was obtained from
Diagnostic International (Schriesheim, Germany). A mono-
clonal anti-GLUT4 antibody (clone 1F8) was obtained
from ANAWA (Wangen, Switzerland). Anti-rabbit and
anti-mouse IgG HRP-conjugated antibodies were from
Sigma. Blots were revealed by chemiluminescence (ECL,
Amersham). Quantitative analysis of bands on films was
done by laser densitometry (ImageQuant 3.3, Molecular
Dynamics).
2.6. RT-PCR analysis
ARC or NRC in one 6-cm dish were extracted in 1 ml
TRIZOL (Life Technologies) and total RNA was purified
Fig. 1. Changes in cell phenotype induced by FGF-2 and IGF-1. ARC were
cultured for 7 days in medium containing the vehicle (A, D), 25 ng/ml FGF-
2 (B, E) or 500 ng/ml IGF-1 (C, F). ARC were fixed and stained for F-actin
(red) and a-sarcomeric actinin (green) in panels A, B and C or for ANF
(red) and a-smooth muscle actin (green) in panels D, E and F. Note that in
panel C, because of the great difference in cell thickness, the image of each
cell was processed separately.
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PCR analysis were performed. In the first approach, 125 ng
total RNAwas used for reverse transcription and subsequent
polymerase chain reaction using the OneStep RT-PCR kit
(Qiagen). Primers capable to coamplify GLUT1 and
GLUT4 cDNAs were used (Table 1), which allowed resolv-
ing their respective products on the basis of a 12-base-pair
size difference [23]. Cycling conditions were as follows: 30
min at 50 jC for reverse transcription, 15 min at 95 jC for
reverse transcriptase inactivation and polymerase activation
followed by 25 cycles of 30 s at 94 jC, 1 min at 55 jC and 1
min at 72 jC. After a final extension step of 10 min at 72
jC, PCR products were resolved by electrophoresis on 10%
polyacrylamide gels in 1X TBE (89 mM Tris–borate, 2 mM
EDTA) buffer. The gels were stained with ethidium bromide
and a fluorescent image acquired with a digital camera.
Quantitative analysis of bands on gel was done with the
NIH Image 1.62 software.
For quantitative real-time RT-PCR, total RNA (100 ng)
was treated with DNase I (Invitrogen) and reverse tran-
scribed with the SuperScript II reverse transcriptase (Invi-
trogen). After degradation of the RNA with RNase H
(Invitrogen), the cDNA was used for real-time polymerase
chain reactions set up with the iQ Supermix kit (Bio-Rad)
and run on an iCycler thermal cycler (Bio-Rad). Cycling
conditions were as follows: 2.5 min at 95 jC for polymer-
ase activation followed by 45 cycles of 15 s at 95 jC and 1
min at 60 jC. Detection of PCR products, based on the
TaqMan technology, was performed by the iCycler iQ
detection and software system (Bio-Rad). Primers and
probes sequences are given in Table 1. The expression of
GLUT4 was normalized for that of the housekeeping gene
cyclophilin.
2.7. Immunofluorescence
ARC cultured on chamber slides were fixed with 4%
paraformaldehyde in PBS and permeabilized with 0.3%
Triton X-100 in PBS. Primary antibodies used were directed
against sarcomeric a-actinin (Sigma A7811), a-smoothTable 1
RT-PCR primers and probes
Duplex RT-PCR [23]
GLUT1/4
Quantitative real-time RT-PCR [28]
GLUT1
GLUT4
Cyclophilinmuscle actin (Sigma A2547), ANF (Peninsula Laboratories
T-4015) or MEF2 (Santa Cruz Biotechnology sc-313).
Fluorophore-conjugated secondary antibodies were anti-
mouse IgG-FITC (Sigma F5262) and anti-rabbit IgG-rho-
damine (Chemicon AQ132R). All antibodies were diluted in
PBS containing 1.5% non-immune goat serum. Counter-
staining for F-actin was obtained with either rhodamine-
phalloidin (Molecular Probes, Eugene, OR) or FITC-phal-Forward: 5V-GTCATCAACGCCCC(A/C)CAGAA-3V
Reverse: 5V-GAGAAGATGGCCACGGAGAGAG-3V
Forward: 5V-CATCGTCGTTGGGATCCTTA-3V
Reverse: 5V-GAGACAGTAGAGGCCACAAGTCT-3V
Probe: 5V-FAM-AGGTGTTCGGCTTAGACTCCATCATGG-TAMRA-3V
Forward: 5V-CCCCCGATACCTCTACAT-3V
Reverse: 5V-GCATCAGACACATCAGCCCAG-3V
Probe: 5V-FAM-CTGCCCGAAAGAGTCTAAAGCGCCT-TAMRA-3V
Forward: 5V-CTGATGGCGAGCCCTTG-3V
Reverse: 5V-TCTGCTGTCTTTGGAACTTTGTC-3V
Probe: 5V-FAM-CGCGTCTGCTTCGAGCTGTTTGCA-TAMRA-3V
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Probes). Slides were mounted with VectaShield (Vector
Laboratories) and examined with a Carl Zeiss Axiophot I
microscope equipped with an Axiocam color CCD camera
(Carl Zeiss). Images were acquired with the AxioVision
software (Carl Zeiss) and processed with Photoshop 3.0.5
(Adobe Systems).
2.8. Electrophoretic mobility shit assay (EMSA)
For nuclear proteins extraction, ARC in 10-cm dishes
were scraped in 2 ml ice-cold hypotonic buffer (20 mM
HEPES pH 7.5, 10 AM Na2MoO4, 0.1 AM EDTA,
protease and phosphatase inhibitors) and left on ice for
10 min. Igepal CA-630 was then added to a final
concentration of 0.5% v/v and the extract was spun at
13000 rpm for 30 s to pellet the nuclei. The pellet wasFig. 2. ARC in primary culture spontaneously upregulate GLUT1 and downregul
vivo ARC or ARC after 2 and 7 days in primary culture. (B) Quantitative analysis
ARC after 2 and 7 days in primary culture. (C) Representative RT-PCR of GLUT1
culture. (D) GLUT4/GLUT1 mRNA molar ratio in ex vivo ARC or ARC after 2 an
by quantitative RT-PCR and expressed as percent of the value in ex vivo ARC. R
##p< 0.01; ###p< 0.001 vs. day 2.resuspended in 40 Al complete lysis buffer (20 mM
HEPES pH 7.5, 400 mM NaCl, 20% glycerol, 1 mM
DTT, 10 AM Na2MoO4, 0.1 AM EDTA, protease and
phosphatase inhibitors) and kept on ice for 30 min with
intermittent shaking. The nuclear extract was then spun at
13,000 rpm for 10 min and the supernatant containing
nuclear proteins saved and stored at  80j C until EMSA
was performed.
The rat glut4 promoter MEF2 probe was constructed by
annealing shifted oligonucleotides (sense 5V-GCCTAACG-
TGGGAGCTAAAAATAGCCATTCCGG-3V; antisense 3V-
TGCACCCTCGATTTTTATC GGTAAGGCCCATG-5V;
MEF2 consensus sequence underlined) and filling in by
the Klenow reaction in the presence of [a-32P]CTP [24].
Nuclear proteins (15 Ag) were incubated with 50,000 cpm
MEF2 probe in complete lysis buffer for 30 min at room
temperature in presence or absence of a 250-fold excess ofate GLUT4. (A) Representative immunoblots of GLUT1 and GLUT4 in ex
of GLUT1 and GLUT4 proteins expression in ex vivo ARC (set at 100%) or
and GLUT4 mRNA in ex vivo ARC or ARC after 2 and 7 days in primary
d 7 days in primary culture. (E) Expression of GLUT4 mRNAwas measured
esults are meanF S.E.M. *p< 0.05; **p< 0.01; ***p< 0.001 vs. ex vivo.
C. Montessuit et al. / Cardiovascular Research 64 (2004) 94–10498unlabeled probe and the complexes were resolved on 5%
non denaturing polyacrylamide gels [24].
2.9. Statistics
Statistical analyses were performed with the Prism4
software (GraphPad Softwares). Multiple groups were
compared by the Kruskal–Wallis test, followed by Dunn’s
post-hoc tests for pair wise comparison. When two treat-
ments were combined (i.e. agonist and inhibitor) results
were analyzed by two-way ANOVA followed by Bonfer-
roni’s post-hoc test. The number of experiments or cells
analyzed is indicated at the foot of each bar in bar graphs.
Differences were considered significant when p was less
than 0.05.Fig. 3. FGF-2 and IGF-1 upregulate GLUT4 expression. ARC were plated
in medium containing 25 ng/ml FGF-2, 50 ng/ml IGF-1, 500 ng/ml IGF-1
or the vehicle. After indicated times, total RNA and proteins were extracted.
(A) Expression of GLUT4 mRNA was measured by quantitative RT-PCR
and expressed as percent of the value in ex vivo ARC.
(B) Expression of the GLUT4 protein was determined by immunobloting.
Results are meanF S.E.M. *p< 0.05; **p< 0.01; ***p< 0.001 vs. control.
Insets show representative Western blots.3. Results
3.1. Spontaneous modification of ARC phenotype and effect
of FGF-2 and IGF-1
Two days following plating of the ARC, cells were
either rod-shaped or rounded up by hypercontraction, with
only minimal cell spreading. No differences were apparent
between control and growth factor-treated ARC. After 7
days in culture, ARC had started to disassemble the
contractile apparatus and spread onto the substratum. A
‘‘myofibrillar ball’’ persisted in the perinuclear region (Fig.
1A). To study the influence of growth factors that have
been shown to promote or attenuate cellular features of
dedifferentiation [15], ARC were cultured in medium
containing, respectively, FGF-2 or IGF-1. In the presence
of FGF-2, ARC were much larger, with myofibrils restrict-
ed to a central perinuclear region (Fig. 1B). Fig. 1C shows
two ARC cultured with 500 ng/ml IGF-1. One cell is fully
spread and shows extensive myofibrillar organization,
while the other essentially shows a ‘‘myofibrillar ball’’.
In contrast to control and IGF-1-treated ARC (Fig. 1D,F),
ARC exposed to FGF-2 exhibited expression of the
markers of myocyte hypertrophy and dedifferentiation
ANF and a-smooth muscle actin. ANF was visible in
perinuclear granules (rhodamine label), while a-smooth
muscle actin was seen in stress fiber-like structures (FITC
label).
3.2. GLUT1 and GLUT4 expression during spontaneous
modification of phenotype of ARC
ARC in long-term culture exhibited spontaneous mod-
ifications of expression of the glucose transporter proteins
GLUT1 and GLUT4. After 2 days in primary culture, the
protein content of GLUT1 was markedly increased com-
pared with the value measured in ARC immediately after
isolation (thereafter referred to as ex vivo ARC). Concom-
itantly, the protein content of GLUT4 was decreased (Fig.2A,B). Coamplification of GLUT1 and GLUT4 mRNA by
RT-PCR using a common set of primers revealed a marked
drop in the GLUT4/GLUT1 mRNA molar ratio in ARC
after 2 days in primary culture as compared to ex vivo ARC
(Fig. 2C,D). Seven days after isolation, GLUT1 protein
expression was further increased, while expression of
GLUT4 was restored to levels even above ex vivo levels.
Consistent with restoration of GLUT4 expression, the
GLUT4/GLUT1 mRNA molar ratio also increased and
reached almost ex vivo levels. Expression of GLUT4
mRNA as measured by quantitative RT-PCR followed a
pattern parallel to that of the GLUT4/GLUT1 mRNA ratio
(Fig. 2E), whereas expression of GLUT1 mRNA did not
change significantly after 2 days and decreased slightly
after 7 days.
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IGF-1 induced a marked increase in GLUT4 protein
expression on both day 2 and day 7. In contrast, FGF2 only
slightly increased the expression of the GLUT4 protein
(Fig. 3B).
Changes at the level of protein expression were paral-
leled by alterations of the GLUT4 mRNA expression. After
2 days, treatment with FGF-2 did not increase the level of
the GLUT4 mRNA, whereas IGF-1 increased the GLUT4
mRNA (Fig. 3A). After 7 days of treatment with IGF-1, the
expression of GLUT4 mRNA was increased more than
twofold. Again, FGF-2 had no effect.
3.4. Signaling pathways involved in regulation of GLUT4
expression
To determine whether signaling pathways were activated
by the isolation procedure itself, measurements in extracts of
hearts obtained immediately after surgical excision (thereaf-
ter referred to as native hearts) were compared to ex vivo
ARC and to ARC kept in culture for 4, 24 and 48 h. An
obvious limitation of this approach is the comparison of a
whole tissue homogenate of native hearts, containing several
cell types, with a 95% pure ARC population. The ERK1/2
MAP kinase and the PI3K pathways were examined, because
these signaling cascades are major determinants of GLUT1
[25] and GLUT4 expression [26,27]. In addition, we mea-
sured activation of the p38 MAPK cascade, which was likely
to be activated in response to the stress of isolation.
Activity of the PI3K pathway, estimated from the
phosphorylation level of the downstream kinase Akt on
C. Montessuit et al. / CardiovaFig. 4. Isolation and growth factors activate MAP kinase pathways. (A) Isolatio
immunoblots showing activated (phosphorylated) and total ERK1/2, p38 MAPK a
and 48 h. (B) Growth factors activate ERK1/2, p38 MAPK and Akt. Representativ
MAPK and Akt in ARC treated with FGF-2 or IGF-1 for 10 min immediately afSer-473, was not stimulated by isolation of the ARC, as the
variations in pSer473-Akt observed between native hearts
and ex vivo ARC paralleled the variations in total Akt
protein. In fact, quantitative analysis indicated that activity
of the PI3K pathway was reduced upon ARC isolation
(Fig. 4A). In contrast, both the ERK1/2 and the p38 MAP
kinase pathways showed marked activation immediately
after isolation. Quantitative analysis of ERK1/2 and p38
MAPK activities revealed a 14- and 9-fold activation upon
isolation, respectively. p38 MAPK activity returned to
baseline within 2 days, whereas ERK1/2 activity remained
elevated.
FGF-2 and IGF-1 elicited a further increase of activation
of ERK1/2 and p38 MAPK 10 min after plating (Fig. 4B).
In addition, IGF-1, but not FGF-2, strongly activated Akt,
which had been inactivated upon isolation.
To elucidate the role of the role of ERK1/2, and p38
MAPK on growth factor-stimulated increase of GLUT4,
ARC were cultured for 2 days with medium containing
growth factors and selective inhibitors. Growth factor stim-
ulation in the presence of an inhibitor was expressed relative
to incubation with the inhibitor alone. It is of note that
U0126 increased basal expression GLUT4 by 294%, while
the p38 MAPK inhibitor SB203580 slightly increased basal
GLUT4 expression. Fig. 5 depicts the effects of inhibitors
on GLUT4 expression. U0126 did not significantly alter
GLUT4 expression in ARC exposed to either FGF-2 or
IGF-1. In contrast, SB203580 completely abolished the
pronounced overexpression of GLUT4 induced by IGF-1
after both 2 (A) and 7 (B) days. Thus, increased protein
expression of GLUT4 in response to IGF-1 seems to be
largely mediated by p38 MAPK.n activates ERK1/2 and p38 MAPK, but deactivates Akt. Representative
nd Akt in native heart extracts, ex vivo ARC and ARC in culture for 4, 24
e immunoblots showing activated (phosphorylated) and total ERK1/2, p38
ter isolation.
Fig. 5. Activation of the p38 MAPK pathway mediates upregulation of
GLUT4. Quantitative analysis of GLUT4 protein expression in ARC after 2
days (A) and 7 days (B) in primary culture in presence of 0.1% DMSO,
U0126 (U; 10 AM) or SB203580 (SB; 10 AM). ARC were also incubated
with FGF-2, IGF-1 or no agonist. For each inhibitor, the results were
normalized for expression in absence of agonist. Results are meanF S.E.M.
**p< 0.01 vs. no agonist; ##p< 0.01 vs. value with the same agonist but no
inhibitor. Insets show representative Western Blots.
 
Fig. 6. Activation of the glut4 promoter by the p38 MAPK pathways. (A)
Quantitative analysis of GLUT4 mRNA expression in neonatal rat
cardiomyocytes (NRC) in primary culture in presence of 0.1% DMSO or
SB203580 (SB; 10 AM). ARC were also incubated with FGF-2, IGF-1 or
no agonist. For each inhibitor, the results were normalized for expression in
absence of agonist. (B) Relative luciferase expression driven by either the
glut4 promoter was determined in NRC cotransfected with expression
plasmids encoding activated MEK1 (DN3MEK1; A), activated MEK6
(MEK6DD, B) or the empty respective vector plasmid. NRC were treated
with the MEK1 inhibitor U0126 (10 AM), the p38 MAPK inhibitor
SB203580 (10 AM) or the vehicle DMSO. Results are meanF S.E.M.
***p< 0.001 vs. empty vector. #p< 0.05; ###p< 0.001 vs. NRC expressing
the same activated MEK in absence of inhibitor.
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activation of the GLUT4 promoter in neonatal rat
cardiomyocytes
The effects of activation of ERK1/2 and p38 MAPK on
transcriptional activity of the glut4 promoters were inves-
tigated in neonatal rat cardiomyocytes (NRC). We resorted
to NRC for these experiments because ARC are not
amenable to conventional transfection techniques. As in
ARC, IGF-1 increased the expression of the GLUT4
mRNA in NRC (Fig. 6A) in a p38 MAPK-dependent
manner.
Transfection of the active ERK1/2 mutant DN3MEK1
did not significantly alter glut4 promoter activity (Fig. 6B).
In contrast, activation of p38 MAPK by MEK6DD elicited
robust stimulation of glut4 promoter activity, which was
entirely blocked by SB203580 (Fig. 6C). Thus, p38 MAPK,
but not ERK1/2, seems to be capable of stimulating glut4
promoter activity.
Fig. 7. MEF2 activation in ARC treated with growth factors. Fixed and permeabilized ARC were stained with anti-a-actinin antibody (green), DAPI (blue) and
anti-MEF2 antibody (red). Nuclei were counted as positive if the MEF2 staining was evident against cytoplasmic background. (A) Example of an ARC with
one MEF2-negative and one MEF2-positive nucleus. (B) Proportions of MEF2-positive nuclei in ARC treated for 2 days with 50 ng/ml IGF-1, 500 ng/ml IGF-
1 or the vehicle in the presence or absence of the p38 MAPK inhibitor SB203580 (10 AM). Error bars indicate the 95% confidence interval of the proportion.
**p< 0.01; ***p< 0.001 for IGF-1 treatment vs. control. #p< 0.05 for SB203580 treatment vs. no inhibitor. (C) Representative electrophoretic mobility shift
assay showing a single specific MEF2 complex, identified by competition with excess cold probe and by supershift with an anti-MEF2 antibody. (D)
Quantitation of MEF2 complexes in nuclear extracts from ARC treated with 50 ng/ml IGF-1, 500 ng/ml IGF-1 or the vehicle in the presence or absence of the
p38 MAPK inhibitor SB203580 (10 AM). Inset shows a representative experiment. *p< 0.05, **p< 0.01 for IGF-1 treatment vs. vehicle. #p< 0.05 for
SB203580 treatment vs. DMSO.
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We tested the hypothesis that, downstream of p38
MAPK, the transcription factor MEF2 mediated the over-
expression of GLUT4 in response to IGF-1. Nuclear reten-tion of MEF2 in fixed permeabilized ARC was used as an
index of increased DNA affinity. The percentage of MEF2-
positive nuclei (i.e. MEF2 staining showing up in the
nucleus against cytoplasmic background, Fig. 7A) was
low in control ARC after 2 days (11% of MEF2-positive
 Fig. 8. Activation of the glut4 promoter by the p38 MAPK pathway is
MEF2-dependent. Relative luciferase expression driven by either the wild-
type glut4 promoter or the glut4 promoter mutated at the MEF2 binding site
(MEF2mut) was determined in NRC cotransfected with an expression
plasmid encoding activated MEK6DD or the empty vector plasmid. Results
are meanF S.E.M. ***p< 0.001 vs. empty vector. #p< 0.05; ##p< 0.01;
###p< 0.001 MEF2mut vs. wild-type glut4 promoter.
C. Montessuit et al. / Cardiovascular Research 64 (2004) 94–104102nuclei, 95% confidence interval 8–16%, n = 212), but
increased after 7 days in parallel with reexpression of
GLUT4 (39% of MEF2-positive nuclei, 95% confidence
interval 32–47%, n = 166). Both dosages of IGF-1 increased
the proportion of MEF2-positive nuclei, an effect that was
blunted by inhibition of p38 MAPK activity with SB20358
(Fig. 7B). Electrophoretic mobility shift assays using the
MEF2 consensus sequence from the rat glut4 promoter
showed a single specific complex of ARC nuclear proteins
with the glut4 MEF2 probe, identified by competition with
excess cold probe and by supershift with an anti-MEF2
antibody (Fig. 7C). The intensity of the MEF2 complex was
greater in nuclear extracts from IGF-1-treated ARC; again,
inhibition of p38 MAPK activity reduced binding ARC
nuclear proteins to the glut4 MEF2 probe (Fig. 7D).
To further confirm the importance of MEF2 for p38
MAPK-stimulated GLUT4 transcription, we mutated the
MEF2 consensus sequence in the reporter plasmid pLuc-
GT4 used in transient transfection experiments in NRC.
Basal transcription from the mutated glut4 promoter was
markedly reduced as compared with the wild-type promoter
(Fig. 8). In addition, transcription from the mutated glut4
promoter was totally insensitive to expression of MEK6DD,
indicating that MEF2 binding activity is required for trans-
duction of the p38 MAPK signals to the glut4 promoter.4. Discussion
Cardiac hypertrophy and failure is associated with down-
regulation of GLUT4, which potentially contributes to
altered myocardial structure, metabolism and function
[11,12]. The results of the present study in ARC indicate
that IGF-1 can restore GLUT4 expression through p38
MAPK-mediated activation of MEF2.4.1. ARC differentiation and GLUT expression
One of the aims of this study was to examine the
relationship between the state of differentiation of cardiac
myocytes and the relative expression of GLUT isoforms,
taking advantage of the dedifferentiation–redifferentiation
ARC model and of the possibility to manipulate the degree
of differentiation. The results demonstrated that isolation of
ARC in itself elicited not only morphological dedifferenti-
ation of the myocytes, but also corresponding changes in the
mRNA and protein expression of GLUT isoforms. Freshly
isolated (ex vivo) ARC had a GLUT4/GLUT1 mRNA
molar ratio of 4.8, a value similar to that reported for native
cardiac tissue (3.8) [23]. After 2 days in primary culture, this
ratio had dropped to 0.65, a value below that reported for
neonatal rat cardiac myocytes (0.84) [25]. During the
subsequent redifferentiation process, GLUT4 protein ex-
pression was increased after 7 days and the GLUT4/GLUT1
mRNA molar ratio was reaugmented to 2.7. Concomitantly
with the effects of FGF-2 and IGF-1 on markers of dedif-
ferentiation such as ANF, a-smooth muscle-actin and myo-
fibrillar organization [14–16], IGF-1 more potently than
FGF-2 restored expression of GLUT4 towards ex vivo
values. This suggests that the GLUT isoform expression
pattern may provide an index of differentiation of cardiac
myocytes. Indeed, similar dysregulation of glucose trans-
porters expression were observed in pathological conditions
challenging cardiac myocytes differentiation such as hyper-
trophy, unloading [28] or failure [9]. The reason why the
GLUT1 protein expression increased whereas the GLUT1
mRNA remained stable or even slightly decreased remains
unknown.
4.2. Signal transduction and regulation of GLUT expression
The marked upregulation of GLUT4 observed in ARC in
response to IGF-1 was completely abolished by the p38
MAPK inhibitor SB203580. This strongly suggests that p38
MAPK is the main effector of GLUT4 upregulation in ARC
in primary culture. Consistent with the effects of inhibition
of ERK1/2 and p38 MAP kinases on GLUT4 expression in
ARC, transfection experiments in NCR indicated that p38
MAPK but not ERK1/2 activate transcription from the
glut4 promoter. Such a positive regulation of GLUT4 by
p38 MAPK has to the best of our knowledge not been
reported. It should be emphasized that FGF-2 and IGF-1
activated p38 MAPK to a similar extent, while the pro-
nounced upregulation of GLUT4 was observed only in the
presence of IGF-1, and only to a small extent in the
presence of FGF-2.
We used a comparatively high dose of IGF-1 (500 ng/ml)
based on previous studies examining the differential effects
of FGF-2 and IGF-1 in the ARC model [15]. A potential
concern with such a high dose of IGF-1 is activation of the
insulin receptor leading to effects that are not specific for
IGF-1. We obtained results that were almost identical when
C. Montessuit et al. / Cardiovascular Research 64 (2004) 94–104 103we used a 10-fold lower dose of IGF-1 (50 ng/ml, Fig. 3).
We do not believe that activation of the insulin receptor
played a significant role in our observations as even the high
dose of IGF-1 (500 ng/ml or ca. 66 nM) was below the
estimated Kd for activation of the insulin receptor by IGF-1
(100–500 nM) [29].
Transcription factors of the Myocyte Enhancer Factor 2
family are required for expression of GLUT4 in adipocytes
and both heart and skeletal muscle [30,31]. MEF2 is known
to be activated by p38 MAPK [32]. Our results clearly
indicate that IGF-1 activated MEF2 in a p38 MAPK-
dependent manner and that MEF2 activation was required
for increased expression of GLUT4 in response to IGF-1.
More nuclei were MEF2-positive in IGF-1-treated ARC,
which indirectly suggests increased affinity of MEF2 for
DNA, preventing diffusion of MEF2 out of the nuclei of
fixed and permeabilized cells. A similar interpretation was
proposed for the glucocorticoid receptor [33]. This conclu-
sion was confirmed by more specific electrophoretic mobil-
ity shift assays measuring the binding of ARC nuclear
proteins to a MEF2 consensus sequence derived from the
rat glut4 promoter. An interesting observation in this context
is that TGF-h inhibits differentiation of myogenic cells
through translocation of MEF2 from the nucleus to the
cytoplasm [34]. It may be speculated that the mechanism(s)
that triggered dedifferentiation of ARC similarly induced
translocation of MEF2 to the cytoplasm.Acknowledgements
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